Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood

Viruses

卷:7

Weronika Beta¹  Karolina Wojtyna¹  Dorota Lecion¹  Jarosław Ciekot¹  Joanna Majewska¹  Agnieszka Piotrowicz¹  Marek Harhala¹  Katarzyna Hodyra-Stefaniak¹  Krystyna Dąbrowska¹  Anna Kłopot¹  Paulina Miernikiewicz¹  Zuzanna Kaźmierczak¹  Agnieszka Kopciuch¹  Mateusz Mąkosa¹  Barbara Owczarek¹ 

[1] Institute of Immunology and Experimental Therapy, PolishAcademy of Sciences, ul. R. Weigla 12, 53-114Wrocław, Poland;

关键词: T4 phage;    EBOV;    Ebola virus;    oral administration;    vaccine;    phage display;    capsid proteins;    antibodies;    phage resistance;   

DOI  :  10.3390/v7082845

来源: DOAJ

【 摘 要 】

A specific humoral response to bacteriophages may follow phage application for medical purposes, and it may further determine the success or failure of the approach itself. We present a long-term study of antibody induction in mice by T4 phage applied per os: 100 days of phage treatment followed by 112 days without the phage, and subsequent second application of phage up to day 240. Serum and gut antibodies (IgM, IgG, secretory IgA) were analyzed in relation to microbiological status of the animals. T4 phage applied orally induced anti-phage antibodies when the exposure was long enough (IgG day 36, IgA day 79); the effect was related to high dosage. Termination of phage treatment resulted in a decrease of IgA again to insignificant levels. Second administration of phage induces secretory IgA sooner than that induced by the first administrations. Increased IgA level antagonized gut transit of active phage. Phage resistant E. coli dominated gut flora very late, on day 92. Thus, the immunological response emerges as a major factor determining phage survival in the gut. Phage proteins Hoc and gp12 were identified as highly immunogenic. A low response to exemplary foreign antigens (from Ebola virus) presented on Hoc was observed, which suggests that phage platforms can be used in oral vaccine design.

【 授权许可】

Unknown